Infection-Mimicking Materials to Program Dendritic Cells In Situ
暂无分享,去创建一个
David J. Mooney | Nathaniel Huebsch | G. Dranoff | D. Mooney | Nathaniel Huebsch | Glenn Dranoff | Lan Cao | Lan Cao | Omar A. Ali | O. Ali
[1] E. Gilboa. DC-based cancer vaccines. , 2007, The Journal of clinical investigation.
[2] Linda G Griffith,et al. Emerging Design Principles in Biomaterials and Scaffolds for Tissue Engineering , 2002, Annals of the New York Academy of Sciences.
[3] Ira Mellman,et al. Dendritic Cells Specialized and Regulated Antigen Processing Machines , 2001, Cell.
[4] A. Krieg. Development of TLR9 agonists for cancer therapy. , 2007, The Journal of clinical investigation.
[5] D J Mooney,et al. Bioabsorbable polymer scaffolds for tissue engineering capable of sustained growth factor delivery. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[6] T. Brocker,et al. Endogenous Dendritic Cells Are Required for Amplification of T Cell Responses Induced by Dendritic Cell Vaccines In Vivo 1 , 2003, The Journal of Immunology.
[7] Y. Yamaguchi,et al. EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation. , 1998, Journal of immunology.
[8] J. Mayordomo,et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity , 1996, The Journal of experimental medicine.
[9] H. Oertel. OBSERVATIONS CONCERNING LEUKÆEMIC LESIONS OF THE SKIN , 1899, The Journal of experimental medicine.
[10] D. Morton,et al. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. , 1998, The Journal of investigative dermatology.
[11] David J Mooney,et al. Fabrication and in vitro testing of polymeric delivery system for condensed DNA. , 2003, Journal of biomedical materials research. Part A.
[12] R. Steinman,et al. Taking dendritic cells into medicine , 2007, Nature.
[13] Robert Langer,et al. Controlled Delivery Systems for Proteins Based on Poly(Lactic/Glycolic Acid) Microspheres , 1991, Pharmaceutical Research.
[14] D J Mooney,et al. Open pore biodegradable matrices formed with gas foaming. , 1998, Journal of biomedical materials research.
[15] M. Kapsenberg. Dendritic-cell control of pathogen-driven T-cell polarization , 2003, Nature Reviews Immunology.
[16] C. Caux,et al. Selective Recruitment of Immature and Mature Dendritic Cells by Distinct Chemokines Expressed in Different Anatomic Sites , 1998, The Journal of experimental medicine.
[17] Dwaine F. Emerich,et al. Cellular transplantation : from laboratory to clinic , 2007 .
[18] S. Cingarlini,et al. Therapeutic Effectiveness of Recombinant Cancer Vaccines Is Associated with a Prevalent T-Cell Receptor α Usage by Melanoma-specific CD8+ T Lymphocytes , 2004, Cancer Research.
[19] G. Asherson,et al. Distribution of immunogenic cells after painting with the contact sensitizers fluorescein isothiocyanate and oxazolone. Different sensitizers form immunogenic complexes with different cell populations. , 1980, Immunology.
[20] D. Mooney,et al. Polymeric system for dual growth factor delivery , 2001, Nature Biotechnology.
[21] E. Jaffee,et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[22] Franco Patrone,et al. The use of dendritic cells in cancer immunotherapy. , 2008, Critical reviews in oncology/hematology.
[23] R Bonecchi,et al. Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. , 1998, Journal of immunology.
[24] M. Merad,et al. In Vivo Manipulation of Dendritic Cells Overcomes Tolerance to Unmodified Tumor-Associated Self Antigens and Induces Potent Antitumor Immunity1 , 2005, The Journal of Immunology.
[25] R. Steinman,et al. Dendritic cells and the control of immunity , 1998, Nature.
[26] Gwendalyn J Randolph,et al. Migration of dendritic cell subsets and their precursors. , 2008, Annual review of immunology.
[27] D. Klinman. Immunotherapeutic uses of CpG oligodeoxynucleotides , 2004, Nature Reviews Immunology.
[28] A. Grothey,et al. Antiangiogenic therapy in cancer: a new era has begun. , 2005, Oncology.
[29] S. Rosenberg,et al. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[30] J. Richards,et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] S. Rosenberg,et al. Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells , 2003, The Journal of experimental medicine.
[32] J. Saurat,et al. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. , 2000, Cancer research.
[33] M. Disis. Clinical use of subcutaneous G-CSF or GM-CSF in malignancy. , 2005, Oncology.
[34] Mary Fischer. Implanon: a new contraceptive implant. , 2008, Journal of obstetric, gynecologic, and neonatal nursing : JOGNN.
[35] R. Coffman,et al. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists , 2007, Nature Medicine.
[36] I. Fidler. Biological behavior of malignant melanoma cells correlated to their survival in vivo. , 1975, Cancer research.